Related Experiment Video
Updated: Sep 7, 2025
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.5K
New Approved Use for Keytruda.
1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .
The American Journal of Nursing
|June 23, 2022
Summary
Pembrolizumab (Keytruda) is now approved for advanced endometrial cancer. This treatment is for patients with microsatellite instability-high or mismatch repair deficient tumors who have not responded to prior therapies.
Area of Science:
- Oncology
- Genetics
Background:
- Endometrial carcinoma is a significant gynecologic malignancy.
- Tumors with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) represent a distinct molecular subtype.
- Limited treatment options exist for advanced or recurrent endometrial cancer.
Purpose of the Study:
- To announce the regulatory approval of pembrolizumab (Keytruda) for a specific patient population with advanced endometrial carcinoma.
- To highlight the efficacy of pembrolizumab as a single agent in this context.
Main Methods:
- This is an approval announcement based on clinical trial data.
- The approval targets patients with advanced endometrial carcinoma.
- Eligibility requires disease progression after prior systemic therapy and unsuitability for curative surgery or radiation.
Main Results:
- Pembrolizumab (Keytruda) has received regulatory approval.
- The drug is indicated for advanced endometrial carcinoma characterized by MSI-H or dMMR.
- This approval applies to patients whose disease progressed despite prior systemic treatments.
Conclusions:
- Pembrolizumab offers a new therapeutic option for a defined subset of patients with advanced endometrial cancer.
- The approval underscores the importance of molecular profiling (MSI-H/dMMR) in guiding treatment decisions for endometrial carcinoma.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
263
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
263
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
227
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
227
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K